RxDoctor Payments Data

Marcy Hanudel, MD

Ophthalmology · Lake Charles, LANPI 1326483462

Payments from drug & device makers

$832in general payments, 2019–2025

Across 30 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$217
  • Alcon$210
  • Carl Zeiss Meditec, Inc.$143
  • Oyster Point Pharma, Inc.$73
  • Johnson & Johnson Surgical Vision, Inc.$54
  • Sight Sciences, Inc.$47
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$68983%
  • Gifts$14317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$832 in reported general payments places this provider in the 30th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$230,522
Medicare patients
847
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine51$49,925
XiidraLifitegrast17$20,772
CombiganBrimonidine Tartrate/Timolol47$18,025
LumiganBimatoprost41$16,234
Prednisolone Acetate272$13,618
RhopressaNetarsudil Mesylate22$8,776
RocklatanNetarsudil Mesylat/Latanoprost20$6,638
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$5,456
MoxifloxacinMoxifloxacin Hcl260$5,344
Cyclosporine11$4,758
SimbrinzaBrinzolamide/Brimonidine Tart24$4,671
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat241$4,575
Latanoprost593$4,048
Travoprost15$3,130
Ketorolac Tromethamine103$2,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$217$84,184139 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$26$15,41442 claims
AlconSimbrinza$210$4,67124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →